Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
1. Ernexa Therapeutics announced a 1-for-15 reverse stock split effective June 12, 2025. 2. The reverse stock split aims to maintain Nasdaq listing by ensuring minimum bid compliance. 3. Post-split, approximately 7.36 million shares will remain outstanding. 4. No changes to shareholder rights or preferences occur due to the split. 5. Reverse split is part of a strategy to strengthen financial foundations.